NERLYNX is a small molecule that provides comprehensive, irreversible, intracellular pan-HER signaling inhibition3,20,30-35,*
NERLYNX PENETRATES THE BLOOD-BRAIN BARRIER
- In preclinical studies using an in vitro model, neratinib, a low-molecular-weight drug, demonstrated the ability to cross the blood-brain barrier
- In preclinical studies, neratinib inhibited key transporters associated with drug resistance in the brain
Tumor growth prevention
- Intracellular binding of neratinib to the receptor tyrosine kinase signaling domain leads to sustained inhibition of HER2 signaling, inducing cell-cycle arrest and apoptosis3,30
- Neratinib inhibits downstream signaling, reducing tumor cell growth and proliferation and inducing tumor cell death in vitro30,32
*As seen in preclinical models.
EGFR: epidermal growth factor receptor; HER: human epidermal growth factor receptor; MAPK: mitogen-activated protein kinase.
Select IMPORTANT SAFETY INFORMATION
Embryo-Fetal Toxicity: NERLYNX can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.
Lactation: Advise women not to breastfeed.
Please see additional IMPORTANT SAFETY INFORMATION below.